{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Number of participants with a response to treatment at that maximal tolerated dose (including partial, very good, or complete responses)","groups":[{"description":"Pomalidomide dexamethasone\n\nPomalidomide: Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-28\n\nDexamethasone: 10-20 mg on days 1, 8, 15, and 22","id":"OG000","title":"Pom Plus Dex"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Number of evaluable patients treated at the maximal tolerated dose of 4mg including the Phase I cohort 3 participants and the Phase II expansion participants","reportingStatus":"POSTED","timeFrame":"one year","title":"Response to the Maximal Tolerated Dose","type":"SECONDARY","unitOfMeasure":"Participants"}